|Bid||4.2300 x 2900|
|Ask||4.4900 x 900|
|Day's Range||4.0200 - 4.3350|
|52 Week Range||4.0200 - 13.5200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.40|
NEW YORK, January 12, 2022--PAVmed and Lucid Diagnostics welcome new full-time investor relations team.
NEW YORK, January 06, 2022--Lucid Diagnostics to participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference.
NEW YORK, December 01, 2021--PAVmed subsidiary Lucid Diagnostics launches EsoGuard telemedicine program in partnership with UpScriptHealth.